| Heading: |
Drugs: Visual Impairment |
| Question ID: |
1798896 |
| UIN: |
49424 |
| House: |
Commons |
| Date tabled: |
2025-04-30 |
| Asking Member ID: |
4676 |
| Asking Member display name: |
Marsha De Cordova
|
| Asking Member handle: |
Marshadecordova
|
| Asking Member Twitter reference: |
@Marshadecordova
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of providing support to the Medicines and Healthcare products Regulatory Agency in reviewing (a) guidance and (b) regulations for the (i) licen |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-05-08 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) already has provision in the current Human Medicines Regulations 2012 No 1916 legislation, to ensure the licensing and packaging of medicines are safe for use by blind and partially sighted pe... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |